Indivior raises profit and revenue guidance after strong start to year
Indivior raises profit and revenue guidance after strong start to year
Read moreWed, 15th May 2019 15:41
Indivior raises profit and revenue guidance after strong start to year
Read moreLONDON MARKET OPEN: Indivior shines after upgrading guidance
Read moreLONDON MARKET PRE-OPEN: Dividend contrast from Dixons and Stagecoach
Read more(Sharecast News) - Opioid addiction treatment maker Indivior lifted its 2021 guidance on Wednesday following a better-than-expected business performance through the first half of the year.
Read moreBROKER RATINGS: UBS cuts Rio Tinto to Sell; Morgan Stanley ups Ocado
Read moreIN BRIEF: Indivior secures license for cannabis disorder treatment
Read more(Sharecast News) - Indivior said on Tuesday that it has teamed up with French biotechnology group Aelis to advance the clinical development of a treatment for cannabis use disorder.
Read more(Sharecast News) - Indivior said on Tuesday that it has teamed up with French biotechnology group Aelis to advance the clinical development of a treatment for cannabis use disorder.
Read moreUPDATE: Pay comes under spotlight at BAE, Indivior and Rio Tinto AGMs
Read moreUK shareholder meetings calendar - next 7 days
Read moreIndivior maintains 2021 guidance as first quarter revenue increases
Read moreIndivior says US filings "administrative", no new Suboxone settlements
Read moreUK earnings, trading statements calendar - next 7 days
Read moreIndivior revamps board after accord with biggest shareholder Scopia
Read more(Sharecast News) - Indivior has given Scopia Capital, its biggest investor, a place on its board as part of a governance overhaul by the prescription drugs group.
Read more